Stay updated on Psilocybin for MDD: Novel Clinical Trial

Sign up to get notified when there's something new on the Psilocybin for MDD: Novel Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Psilocybin for MDD: Novel Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:57:23.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a shift in the dosage comparison between a single 25 mg oral dose of psilocybin and a single 100 mg oral dose of niacin for major depressive disorder (MDD) in a clinical trial setting.
    Difference
    0.1%
    Check dated 2024-06-06T14:49:22.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage's 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying age range, ability to swallow capsules, and birth control requirements, among other criteria. Previously, it only stated 'No information provided.'
    Difference
    13%
    Check dated 2024-05-22T21:29:55.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:27:58.000Z thumbnail image

Stay in the know with updates to Psilocybin for MDD: Novel Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Psilocybin for MDD: Novel Clinical Trial page.